Provectus Biopharmaceuticals, Inc.
PVCT
$0.07
$0.017.88%
OTC PK
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -22.99% | -62.37% | |||
| Gross Profit | 22.99% | 59.67% | |||
| SG&A Expenses | -8.41% | -4.93% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -12.34% | -32.61% | |||
| Operating Income | 12.34% | 30.30% | |||
| Income Before Tax | 11.77% | 28.54% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 11.77% | 28.54% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -77.24% | -67.37% | |||
| Net Income | 11.16% | 27.73% | |||
| EBIT | 12.34% | 30.30% | |||
| EBITDA | 12.34% | 30.30% | |||
| EPS Basic | 9.68% | 27.91% | |||
| Normalized Basic EPS | 11.11% | 28.00% | |||
| EPS Diluted | 9.68% | 27.91% | |||
| Normalized Diluted EPS | 11.11% | 28.00% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||